Sampériz G, Guerrero D, López M, Valera J L, Iglesias A, Ríos A, Campins A, Sala E, Murillas J, Togores B, Palmer J, Rodriguez M, Soriano J B, Sauleda J, Riera M, Agusti A
Fundación de investigación Sanitaria de las Islas Baleares Ramon Llull (FISIB), Palma de Mallorca, Spain; Son Espases University Hospital, Palma de Mallorca, Spain.
HIV Med. 2014 Jul;15(6):321-9. doi: 10.1111/hiv.12117. Epub 2013 Dec 8.
Pulmonary abnormalities are often present in patients infected with the human immunodeficiency virus (HIV).
The aim of the study was to determine the prevalence and characteristics of, and risk factors for, pulmonary abnormalities in HIV-positive patients.
A total of 275 HIV-positive patients [mean (± standard deviation) age 48.5 ± 6.6 years] were included in the study, of whom 95.6% had been receiving highly active antiretroviral therapy (HAART) for a mean (± standard deviation) duration of 11.9 ± 5.4 years. The median (interquartile range) CD4 lymphocyte count was 541 (392-813) cells/μL, and 92% of the patients had an undetectable viral load. We determined: (1) spirometry, static lung volumes, lung diffusing capacity, pulmonary gas exchange and exercise tolerance, and (2) the amount of emphysema via a computed tomography (CT) scan.
Chronic cough and expectoration (47%) and breathlessness during exercise (33.9%) were commonly reported. Airflow limitation (AL) was present in 17.2%, low pulmonary diffusing capacity in 52.2% and emphysema in 10.5-37.7% of patients, depending on the method used for quantification. Most of these abnormalities had not been diagnosed or treated previously. Smoking exposure and previous tuberculosis were the main risk factors for AL, whereas smoking exposure and several variables related to HIV infection appeared to contribute to the risk of emphysema and low diffusing capacity.
Despite HAART, pulmonary structural and functional abnormalities are frequent in HIV-positive patients. They are probably attributable to both environmental (smoking and tuberculosis) and HIV-related factors. Most of these abnormalities remain unnoticed and untreated. Given the relatively young age of these patients, these results anticipate a significant health problem in the next few years as, thanks to the efficacy of HAART, patients survive longer and experience the effects of aging.
感染人类免疫缺陷病毒(HIV)的患者常出现肺部异常。
本研究旨在确定HIV阳性患者肺部异常的患病率、特征及危险因素。
共纳入275例HIV阳性患者[平均(±标准差)年龄48.5±6.6岁],其中95.6%的患者接受高效抗逆转录病毒治疗(HAART)的平均(±标准差)疗程为11.9±5.4年。CD4淋巴细胞计数的中位数(四分位间距)为541(392 - 813)个/μL,92%的患者病毒载量检测不到。我们测定了:(1)肺量计、静态肺容积、肺弥散能力、肺气体交换和运动耐力;(2)通过计算机断层扫描(CT)确定肺气肿的程度。
常见的症状有慢性咳嗽咳痰(47%)和运动时呼吸困难(33.9%)。根据量化方法的不同,气流受限(AL)的发生率为17.2%,肺弥散能力降低的发生率为52.2%,肺气肿的发生率为10.5% - 37.7%。这些异常大多既往未被诊断或治疗。吸烟暴露和既往肺结核是AL的主要危险因素,而吸烟暴露以及与HIV感染相关的几个变量似乎与肺气肿和肺弥散能力降低的风险有关。
尽管接受了HAART治疗,HIV阳性患者肺部结构和功能异常仍很常见。这可能归因于环境因素(吸烟和肺结核)以及与HIV相关的因素。这些异常大多未被注意到且未得到治疗。鉴于这些患者相对年轻,由于HAART的疗效使患者存活时间更长并经历衰老的影响,这些结果预示着未来几年将出现重大的健康问题。